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Idiopathic membranous nephropathy is a common cause of
nephrotic syndrome whose pathogenesis may involve B-cell
functions. Rituximab is a monoclonal antibody that binds to
the CD20 antigen on B cells thereby deleting them. We
conducted an open-label pilot trial of rituximab treatment in
15 severely nephrotic patients with proteinuria refractory to
angiotensin-converting enzyme inhibition and/or receptor
blockade but with adequately controlled blood pressure.
Rituximab was given 2 weeks apart and, at 6 months,
patients who remained proteinuric but had recovered B-cell
counts were given a second course of treatment. Proteinuria
was significantly decreased by about half at 12 months.
Of the 14 patients who completed follow-up, full remission
was achieved in two and partial remission in six patients
based upon the degree of proteinuria. Side effects were
minor; however, we found no relationship between the
response and number of B cells in the blood, CD20 cells in
the kidney biopsy, degree of tubulointerstitial fibrosis,
starting proteinuria or creatinine values. Rituximab appears
effective in reducing proteinuria in some patients with
idiopathic membranous nephropathy but prospective
identification of responsive patients was not possible.
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Idiopathic membranous nephropathy (IMN) is the most
common cause of nephrotic syndrome in Caucasian adults
and the second or third cause of a primary glomerulopathy
leading to end-stage renal disease.1 Although, in most
patients, the disease progresses relatively slowly, approxi-
mately 40% of patients eventually develop end-stage renal
disease.2 Current treatment options include corticosteroids,
alkylating agents, cyclosporin A, mycophenolate mofetil, and
tacrolimus, but their use may be associated with significant
adverse effects and is not effective in all patients. Experi-
mental data in MN suggest that B-cell activation results in
immunoglobulin deposition along the glomerular basement
membrane causing injury to the membrane and subsequent
proteinuria.3 In humans, there is evidence that therapy
directed against B cells, for example, cyclophosphamide, is
effective in MN.4 Cyclophosphamide has striking, but non-
selective, effects on B-cell function and suppresses the
secretion of immunoglobulins.5 Thus, a case could be made
for using an agent capable of selectively depleting B cells and
therefore halting the production of immunoglobulins
directed against antigen(s) present in the glomeruli, and
improving or even resolving the glomerular pathology and
reducing proteinuria. There is evidence that this strategy is
effective in the treatment of other antibody-mediated diseases
such as systemic lupus erythematosus and rheumatoid
arthritis (RA).6–8 Rituximab, a monoclonal antibody (mAb)
against the CD20 antigen present on B cells, was approved by
the Food and Drug Administration (FDA) in 1997 for the
treatment of relapsed or refractory non-Hodgkin’s lympho-
ma and more recently for patients with RA. Because the
CD20 antigen is not expressed on hematopoietic stem
cells, normal plasma cells, or other normal tissues, the
use of this mAb allows for selective depletion of B cells.
Recently, Ruggenenti et al.2 treated eight patients with
IMN and nephrotic syndrome with four weekly doses of
rituximab (375 mg m2) and followed them for 1 year.9
Treatment resulted in a 60% reduction in urinary protein
excretion with notably modest side effects and no major
adverse events. However, the patient’s response to rituximab
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was quite variable and the reasons for that variability are not
clear.
Given these encouraging preliminary results, we prospec-
tively treated 15 patients with IMN with rituximab 1 g i.v.
(intravenous) on days 1 and 15. We also studied the
pharmacokinetics (PK) and pharmacodynamics (PD) since
previously no studies had evaluated the effect of proteinuria
on these parameters despite its increasing frequency of use in
autoimmune diseases such as vasculitis, systemic lupus
erythematosus, and RA.6,10,11 We wanted these measurements
since we postulated that in patients with IMN and non-
selective proteinuria, rituximab, an IgG monoclonal protein,
may be lost in the urine affecting its PK and PD and perhaps
its therapeutic efficacy.
We also addressed the question of whether renal pathology
might help in the study of either pathogenesis or patient
responsiveness to this agent. We did this by examining the
specific cellular markers in the renal tissue as well as the
degree of tubular interstitial damage in the biopsies of the
study patients. Previous studies have demonstrated B-cell
infiltrates in increased number in renal biopsies from patients
with IMN, and it has been hypothesized that they could play
a role in the pathogenesis of the disease.12 In contrast, other
studies have suggested that the degree of fibrosis may portend
unresponsiveness to this agent.13 Finally, the formation of
human anti-chimeric antibodies (HACAs) may be induced
by administering any chimeric mAb such as occur with the
anti-tumor necrosis factor mAb infliximab. We tested for the
development of these antibodies since their appearance may
affect the efficacy of rituximab.
RESULTS
Patient characteristics
Fifteen patients (13 men and 2 women), age 4778 years
(mean7s.d.) were enrolled. Seven patients had failed
previous immunosuppressive treatment: two patients had
received prednisone alone (n¼ 2); combined prednisone and
cytotoxic agent (n¼ 2); cyclosporin A (n¼ 2); and myco-
phenolate mofetil (n¼ 1). All patients were severely ne-
phrotic. At entry, systolic and diastolic blood pressures
averaged 130714 and 7679 mm Hg, respectively. The mean
serum creatinine was 1.470.5 mg per 100 ml and the mean
creatinine clearance was 85.2728 ml per min per 1.73 m2.
The mean time from the diagnostic biopsy to entrance into
the study was 13.1713.6 months (range: 6–60) (Table 1).
Outcome
In the 14 patients who completed 12 months of follow-up,
proteinuria decreased from 13.075.7 g per 24 h (range:
8.4–23.5) to 6.077.3 g per 24 h at 12 months (mean7s.d.)
(Po0.05) (Figure 1 and Table 2). Ten patients who had
proteinuria 43 g per 24 h and 415 CD19þ B cells per ml at
6 months were retreated with a second identical course of
rituximab. Prior to the 6-month point and repeat rituximab
treatment, four patients had achieved a partial remission
(PR) and were not retreated. By the end of 12 months,
complete remission (CR) (proteinuria o0.3 g per 24 h) was
achieved in two patients and PR (o50% peak value and
o3 g per 24 h) in six patients. The mean drop in proteinuria
from baseline to 12 months was 6.274.8 g or a 48%
reduction (P¼ 0.0003, paired t-test). The reduction in
proteinuria was gradual, and in patients who responded to
treatment, the lowest level was not achieved until month 12.
This meant that the exact role of the second course of therapy
was hard to determine since in all cases but one proteinuria
was already reduced from baseline value at 6 months in all
patients who went to achieve a PR or CR by 12 months. In
the five patients who did not respond, proteinuria at 6
Table 1 | Main clinical and laboratory characteristics at study entry (baseline) of individual patients with IMN
Patient number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Age (years) 63 37 53 60 33 53 53 45 46 44 46 42 52 38 40
Gender (male/female) M F M M M M M M M F M M M M M
Disease duration (months) 6 10 6 13 5 13 7 10 8 8 60 28 6 10 6
Histology stage (I–IV) I–II I–II III–IV II II I–II II I II II–III I II II I II
Urinary protein excretion (g per 24 h) 9.0 8.4 8.5 20.0 10.8 23.5 16.6 8.8 10.1 6.1 15.8 7.8 14.7 23.4 11.8
Serum creatinine 1.5 0.9 1.3 2.6 1.1 1.8 1.8 1.0 1.3 0.7 2.1 1.2 1.5 1.8 1.0
Creatinine clearance (ml per min per 1.73 m2) 63 102 75 40 109 58 59 114 81 116 61 145 74 68 113
IMN, idiopathic membranous nephropathy.
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Figure 1 | Box plots of urine protein by months since start of
rituximab therapy. The top and bottom of the box are the
estimated 75th and 25th percentiles, respectively. The intermediate
horizontal line and ‘þ ’ sign represent the median and mean urine
protein, respectively. The vertical lines extend to the largest
(smallest) data point, that is, within 1.5 times the interquartile range
(75th–25th percentile) above the 75th percentile (or below the 25th).
The number of patients with follow-up at 0, 1, 3, 6, 9, and 12 months
are 15, 15, 15, 14, 14, and 14, respectively.
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months was not significantly different from baseline and was
unaltered by the second course of rituximab. The reduction
in proteinuria was paralleled by a progressive and significant
increase in serum albumin levels from 2.370.6 g per 100 ml
at baseline (o3 g per 100 ml in 13/15 patients; 87%) to
3.570.8 g per 100 ml at 12 months (o3 g per 100 ml in 4/14
patients; 28%), respectively (mean7s.d.), representing a 53%
increase over basal levels (Table 3). There were significant
changes in serum IgG and IgM levels with baseline IgG levels
increasing and IgM levels falling at 12 months while serum
IgA levels remained relatively stable (Table 3). Total serum
cholesterol and triglyceride levels also decreased progressively
by 12 months (Po0.05, paired t-test) (Table 3 and Figure 2).
The reduction in proteinuria was paralleled by a progressive
and significant decline in body weight (95.5712 kg at
baseline versus 92.1711 kg at month 12; Po0.05, Table 3)
likely reflecting decreasing peripheral edema. Systolic and
diastolic blood pressures were stable during the study. Taking
the group as a whole, renal function did not change
significantly during the 12-month period of the study. The
serum creatinine concentrations at baseline and at 12 months
were similar (1.470.5 versus 1.671.0 mg per 100 ml; P¼not
significant (NS); Table 3). Similarly, there were no significant
changes in 24 h creatinine clearances obtained at baseline
versus at 12 months (85.2728 versus 85.6737 ml per min
per 1.73 m2, respectively; P¼NS). However, in the two
patients who had the lowest creatinine clearance at entry
(40 and 59 ml per min per 1.73 m2), proteinuria remained
unchanged, renal disease was progressive, and both patients
reached end-stage renal disease at 6 and 7 months after
completion of the study.
Total B-cell counts
Initial CD19þ B-cell depletion was seen in all patients
(mean 307.87203 at baseline versus 5.6 cells per ml at day
28). At 3 months, CD19þ B cells were starting to recover
Table 2 | Time course of urinary protein excretion (g per 24 h) in individual patients with IMN from entry into the study
(baseline) to end of study (month 12)
Patient no. Month 6 Baseline Month 1 Month 3 Month 6 Month 9 Month 12 Baseline to month 12a
1b 10.6 9.1 7.4 5.9 18.8 7.4 7.7 1.4
2b 12.9 8.4 8.9 6.3 3.9 2.2 0.6 7.8
3 7.9 8.5 6.1 1.2 0.6 0.4 0.2 8.3
4b 16.4 20.1 16.5 21.8 17.9 15.4 20.2 0.14
5 8.6 10.8 5.5 1.7 1.1 0.8 0.2 10.5
6 13.3 23.5 31.3 5.0 — — — —
7b 10.4 16.6 7.5 14.8 17.2 17.3 19.9 3.3
8 4.6 8.8 3.6 2.2 0.8 0.7 1.0 7.8
9b 7.7 10.1 8.9 7.5 4.8 8.1 0.7 9.4
10b 4.8 6.1 3.9 5.7 6.0 0.6 0.3 5.8
11 7.9 15.8 16.5 3.8 2.1 3.8 0.9 14.9
12b 12.4 7.8 3.8 1.8 4.9 3.5 2.6 5.2
13b 8.9 14.7 14.0 22.4 16.9 12.5 6.0 8.7
14b 12.3 23.4 16.4 22.0 26.5 17.4 14.1 9.4
15b 8.8 11.8 9.2 15.2 8.9 11.1 9.8 2.0
Mean 9.8 13.0 10.6 9.8 9.3 7.2 6.0 6.2
s.d. 3.1 5.7 7.3 7.9 8.4 6.5 7.3 4.8
Median 8.9 10.8 8.9 5.9 5.5 5.6 1.8 7.8
IMN, idiopathic membranous nephropathy.
aPaired t-test P=0.0003 for 12-month change.
bPatients who underwent retreatment with rituximab.
Table 3 | Main clinical and laboratory parameters in 14 patients with IMN from rituximab administration (baseline) to study
end (month 12)
Baseline Day 28 3 months 6 months 9 months 12 months
Systolic BP (mm Hg) 131714 129719 124714 127716 122712 131720
Diastolic BP (mm Hg) 7679 77713 7678 75713 7278 79712
Body weight (kg) 95.5712 95710 91711a 93710 93713a 92711a
Serum creatinine (mg per 100 ml) 1.470.5 1.570.5 1.570.6 1.570.8 1.470.7 1.671.0
Serum albumin (g per 100 ml) 2.370.6 2.770.5a 2.970.7a 3.070.8a 3.270.9a 3.570.8a
Serum IgG (g per 100 ml) 4687345 4937289 5877265a 6807283a 7687377a 7457301a
Serum IgM (g per 100 ml) 105748 105747 83.5742a 78744a 68730a 61728a
Serum IgA (g per 100 ml) 193780 208793 17970.64 194758 187768 176774
Serum cholesterol (mg per 100 ml) 332782 297791a 271777a 259785a 2507101a 215769a
Serum triglycerides (mg per 100 ml) 3397218 3817217 2837217a 2857171 2407184a 2417175a
BP, blood pressure; Ig, immunoglobulin; IMN, idiopathic membranous nephropathy.
Mean7s.d.
aPp0.05 versus month 0.
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(mean 35.8746 cells per ml, range: 1–152), with five patients
having 435 cells per ml. By 6 months, the majority of
patients had counts in the normal range (mean 110797 cells
per ml, range: 28–317). However, no association was seen
between baseline proteinuria and changes in CD19þ B-cell
depletion at 6 months (r¼ 0.244; P¼NS) and 12 months
(r¼ 0.231; P¼NS). There were no significant changes in
hemoglobin levels, total white blood cells, or platelet counts
(Table 4).
Pharmacokinetic studies
Data from our PK studies in the 15 treated patients show
rituximab levels of 218.6767 mg ml1 (mean7s.d.) 1 day
after the first dose, 17711 mg ml1 on day 15 pre-dose, and
205.27111 mg ml1 on day 15 post-dose. There were no
differences in serum rituximab levels at any point between
patients who responded to treatment versus non-responders.
Human anti-chimeric antibodies
Immunodepletable HACAs were detected in six patients at
various time points during the study. In one patient with
the lowest antibody level, HACA became negative with
follow-up. In the other five patients, HACA remained
positive to the end of the study. The presence of HACA
was not associated with responders versus non-responders.
Quantification of CD20þ B cells, CD3þ T cells, and degree
of interstitial fibrosis on renal biopsies
We found no relation between the total number of CD20þ
or CD3þ cells, the ratio of CD20þ /CD3þ cells, or the
number of CD20þ cells per mm2 present in the diagnostic
renal biopsies and the response to rituximab treatment.
CD20þ cells were 0.8870.7 mm2 in the responders versus
5.676.2 mm2 in the non-responders (P¼NS). At the
time of diagnosis, interstitial fibrosis occupied 6.072.2%
(range: 3.2–11.2%) of the renal biopsy area.
Adverse events
The adverse events observed were mainly infusion-related
reactions and none were serious. Three patients developed
itching, rigors, and a skin rash during infusion. Three
patients complained of sore or scratchy throat during
infusion. One patient developed muscle pain after infusion
that resolved with the use of non-steroidal medication. One
Table 4 | Main hematology parameters in 14 patients with IMN from rituximab administration (baseline) to study end
(month 12)
Parameter Baseline 1 month 3 months 6 months 9 months 12 months
Hemoglobin (g per 100 ml) 13.671.2 13.071.4 13.071.5 13.271.8 13.471.7 13.371.9
White blood cell count (3.5–10.5 103ml1) 6.671.3 5.471.3 5.771.2 6.571.4 6.571.2 6.071.2
Lymphocytes (0.66–4.6 103ml1) 1.970.5 1.470.4 1.470.3 1.470.3 1.470.4 1.470.3
Lymphocyte sub-populations
CD19 (71–567ml1) 3087203 5.676.7a 36746a 110797b 88777b 1037108b
CD19 (5–25%) 15.177.8 0.270.5a 2.874.5a 8.177.4b 6.877.3b 8.4710.7
IMN, idiopathic membranous nephropathy.
aPo0.01 and bPp0.05 versus month 0.
cNormal ranges in parentheses.
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Figure 2 | Changes in serum IgG, IgA, and IgM levels following treatment with rituximab. *Po0.05.
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patient developed a serum sickness-like syndrome. Small
patches of hair loss and thinning were observed in two
patients. One patient was diagnosed with community-
acquired pneumonia 3 months after the first infusion that
resolved with oral antibiotic treatment. This patient was
retreated without complications. One patient experienced
fatigue and voice loss soon after the infusion ended, but
recovered spontaneously. One patient with a history of herpes
zoster prior to enrollment in the study developed viral
reactivation. This patient was treated with oral anti-viral
drugs and made a full recovery. One patient was diagnosed
with adenocarcinoma of the lung 3 months after the first
infusion. This patient had a normal chest X-ray 1 year prior
to enrollment. Lung cancer was diagnosed from a computed
tomography scan performed to assess coronary artery
calcification. Participation in the study was discontinued.
The patient subsequently died.
DISCUSSION
This is the largest study to date to prospectively evaluate the
effect of rituximab in patients with IMN. In this study,
rituximab appears to be effective in reducing proteinuria in a
significant number of patients with IMN with severe
nephrotic syndrome and relatively well-preserved renal
function. Reduction in proteinuria was accompanied by
significant increases in serum albumin levels, improvements
in hyperlipidemia, and amelioration of edema. CR of
proteinuria was achieved in two patients while PR was seen
in six patients. When taken together, a CR or PR occurred in
8 of 14 patients (nearly 60%) who completed 1 year of
follow-up. Renal function remained stable in the majority of
patients. We consider this outcome to be very good at least in
the short term, since, based on evidence garnered from the
older literature in which patients did not have the benefit of
anti-proteinuric and kidney-protective therapies that we
currently use, and were used in our patients, persistent heavy
proteinuria is almost invariably associated with progressive
loss of renal function in patients with IMN.14 In both,
diabetic and non-diabetic nephropathy patients, angiotensin
(Ang)-converting enzyme inhibitor (ACEi) and/or Ang II
receptor blockers (ARBs) reduce proteinuria and slow
progression of renal disease. The degree of protection,
however, is related to the degree of proteinuria reduction
and if proteinuria is not lowered, the benefit is substantially
attenuated.15,16 The most recent data from RENAAL study
confirm these observations in that the renal protective effect
of Ang II blockade was nearly fully explained by its anti-
proteinuric effect.17 It is also important to acknowledge the
marked dichotomy in the results with five patients having no
significant improvement in proteinuria despite two full
courses of the rituximab therapy. In addition, the two
patients with the lowest creatinine clearances at baseline
developed progressive renal failure and reached end-stage
renal disease soon after completing the study. These overall
results are in agreement with previous work by Ruggenenti
et al. who prospectively treated eight patients with lower
degrees of proteinuria (8.674.2 g per 24 h at baseline) with
four weekly doses of rituximab (375 mg m2) and found a
significant decrease in proteinuria to an average of 3.072.5 g
per 24 h (66%, Po0.005) at 12 months. Two patient’s
proteinuria had decreased to o0.5 g per 24 h and in three
others to o3.5 g per 24 h. Renal function remained stable in
all patients. Adverse effects were reported as mild.2,9
In patients with lymphoma and in patients with anti-
neutrophil cytoplasmic antibody (ANCA)-associated vascu-
litis and subnephrotic range proteinuria, treatment with
rituximab had minor effects on total serum immunoglobulin
levels.10,18 We postulate that the increase in serum IgG levels
seen in our study may reflect a reduction in urinary losses of
IgG resulting from improvement in the filtration barrier,
while the decrease in IgM levels may reflect the depletion of
IgM-producing B cells by rituximab and/or normalization of
hepatic production with decreasing proteinuria. The increase
in serum IgG levels may have accounted for the reduced
infectious complications seen in our study and may be a
significant and important difference from higher infection
rates seen with the use of broader immunosuppressive
regimens.
It is possible, given the heterogeneous course of the disease
and the absence of a control group, that the beneficial effect
observed was due to spontaneous remission rather than a
therapeutic effect of rituximab. We find this explanation
unlikely because although the traditional concept is that IMN
has a rate of spontaneous remission close to 30%, this
outcome is very rare in a cohort such as we selected with
prolonged high-grade proteinuria. Previous data have
indicated that the majority of spontaneous remissions occur
within the first 2 years of initial presentation and is more
common in females and in patients with subnephrotic range
proteinuria.19 Untreated patients with heavy proteinuria
(48 g per 24 h) rarely remit spontaneously and their clinical
course is characterized by progressive renal failure.20 All
patients in our study had high-grade proteinuria that was
increasing despite maximum tolerated renin–angiotensin
aldosterone system blockade, including dual Ang II blockade
with an ACEi and ARB treatment in eight patients. Other
potential confounding factors, such as a low-protein diet, the
degree of blood pressure control, statin use, and ACEi or ARB
use, had all been introduced 44 months prior to rituximab
treatment and were maintained unchanged during the study.
We performed PK and PD analyses on our patients to
determine whether this might provide further information
about the basic mechanism of the disease or help in the
determination of some prognostic factor that might allow
more appropriate targeting of this therapy in the IMN patient
population. Data from our PK studies in the 15 IMN treated
patients show serum rituximab levels to be significantly lower
than levels found in 38 non-proteinuric patients with RA who
were given the same dosing regimen and measured by the
same method and according to the same schedule as our
patients, in whom levels of 3417212, 65723, and
415794 mg ml1 were found at the same comparable time
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points as our cohort (Po0.001; RA versus IMN at day 1 post-
infusion, day 15 pre-infusion, and day 15 post-infusion,
respectively; Genentech Inc., unpublished observations). The
half-life of rituximab is 3 weeks, with rituximab PK showing
biphasic disposition. We could not calculate the area under
the curve because there were no PK data between days 1 and
15 (distribution phase). Usually, however, area under the
curve is highly correlated with peak and trough concentra-
tions.
Treatment of patients with non-Hodgkin’s lymphoma
(NHL), with either a 4- or 8-week course of rituximab,
results in predictable and profound depletion of normal B
cells from the circulation (to p1% of baseline CD19þ cell
counts).18,21 In these patients, reconstitution of normal B
cells typically begins at 6 months, with the majority of
patients achieving normal circulating B-cell counts by 1 year
following therapy. Similarly, in patients with IMN, the use of
the 4-week (375 mg m2) lymphoma protocol resulted in
B-cell depletion that was maintained up to 12 months after
treatment.2 This profound B-cell depletion is similar to the
B-cell depletion observed in our own studies in ANCA-
associated vasculitis.10 However, these observations are in
clear contrast with this study, in which CD19þ B-cell
recovery was already observed by 3 months and reached the
normal range in all patients by 6 months. This recovery was
also faster than that observed in RA patients treated with the
identical dose and schedule of rituximab infusions (Figure 3).
Data to support that either the dose or frequency of
infusion may influence the duration and/or the extent of
depletion are derived from Zaja et al.,22 who found that bone
marrow CD20þ cells may be more resistant to depletion.
These investigators reported that while total depletion of
CD19þ B cells was observed in the circulation, depletion of
CD20þ cells in the bone marrow occurred in only two of
seven patients who had been treated with 375 mg m2 for 4
weeks.22 Thus, peripheral blood B-cell count does not
correlate uniformly with total body CD20þ B-cell number,
although it is unclear if this can affect the response to
treatment. Similarly, PK studies in lymphoma populations
have shown wide individual variability in drug half-life as
well as a longer half-life with the four-dose protocol.23 While
tumor burden contributes to drug variability through
binding and consumption of rituximab, there are other
potentially important additional factors that may be relevant
to the efficacy of rituximab in IMN. High-grade proteinuria
may lead to losses of rituximab in the urine, a shortened half-
life of the antibody, and therefore potentially reduce
effectiveness of rituximab. Certainly, the faster B-cell recovery
observed in patients with IMN when compared with the rate
of B-cell recovery in patients with RA or ANCA-associated
vasculitis suggests that the duration of B-cell depletion in the
peripheral blood may be in part related to the drug levels.
This we believe is a rational hypothesis, but we have no direct
data to support it since rituximab levels in the urine are not
currently measurable, nor could we find a correlation
between rituximab levels and the degree of proteinuria or
its response. In addition, other disease-specific factors may
play a role in the kinetics of the drug (for example,
differences in volume of distribution).
The findings that rituximab levels are lower and B-cell
depletion is shorter in proteinuric patients may indicate that
the use of 1 g every 2 weeks (versus dosing based on the body
surface area; for example, 375 mg m2 weekly for 4 weeks)
will result in under-dosing and may interfere with the
response to treatment. Two patients had incomplete deple-
tion with CD19þ counts of 18 and 23 cells per ml at day 28,
and in these patients proteinuria was unchanged following
rituximab therapy. However, the fact that there were no
differences in serum rituximab levels between patients who
responded to treatment versus non-responders would argue
against this contention. Furthermore, despite the selection of
patients with more severe disease (mean proteinuria 1375.7
versus 8.674.2 g per 24 h), the proportion of PR or CR
observed in our study is not substantially different than that
reported by Ruggenenti et al.2 with the use of a different
regimen that would give a higher dose of rituximab.
Rituximab is a genetically engineered, chimeric, IgG1k
mAb containing murine light- and heavy-chain variable
region sequences and human constant region sequences. The
formation of HACA may be induced by administering any
chimeric mAb and is well documented for the anti-tumor
necrosis factor mAb infliximab. However, the formation of
HACA after rituximab therapy is uncommon. In a phase II
trial of 58 patients with non-Hodgkin’s lymphoma who
received rituximab (375 mg m2), no patient developed
HACA.24 The rare occurrence of HACA after rituximab
therapy may be related to the main effect of the drug: the
abolition of primary and memory humoral responses.25 On
the other hand, the underlying disease itself may affect the
propensity for antibody formation as reported by Looney
et al.,11 who found detectable HACA in 30% of patients with
systemic lupus erythematosum treated with rituximab. Other
factors may also affect HACA development such as the ethnic
make up of the patient population and/or the use of
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Figure 3 | Dynamics of CD19þ B cells in patients with IMN versus
RA versus ANCA-associated vasculitis. Patients with IMN and RA
were treated with rituximab 1 g i.v. on days 1 and 15. Patients with
ANCA-associated vasculitis received rituximab 375 mg m2 i.v. on
days 1, 8, 15, and 22.
122 Kidney International (2008) 73, 117–125
o r i g i n a l a r t i c l e FC Fervenza et al.: Rituximab in membranous nephropathy
concomitant cytotoxic or immunosuppressive agents.
Although such antibodies are not associated with clinical
symptoms,11,26 following repeated drug administration they
may contribute to adverse effects or retard B-cell depletion.
In our study, HACA developed in 6 out of 14 (43%) patients
followed for 1 year. However, despite all these theoretical
reasons for a difference dependent on any or all of these
factors, we found no correlation between the severity of
proteinuria, rituximab levels, the degree of B-cell depletion,
the presence of HACA, and the development of side effects
between our responders and non-responders.
Although a number of studies have identified predictors of
renal disease progression in IMN, very little is known
regarding factors that may predict responses to therapy. More
recently, Ruggenenti et al.13 retrospectively evaluated clinical,
laboratory, and histology covariants in 14 patients with IMN
and proteinuria 43.5 g per 24 h who had been treated with
rituximab and identified a higher score composed of the
degree of tubulointerstitial changes (tubulointerstitial atro-
phy and interstitial fibrosis) as the best predictor of response
to therapy. At 12 months after rituximab therapy, proteinuria
decreased to o3 g per 24 h in four patients and to o1 g per
24 h in two patients with a tubulointerstitial score of o1.7,
while there was no substantial improvement in proteinuria in
patients with more significant tubulointerstitial score.
In our study, in contrast, the degree of interstitial fibrosis
present in the initial biopsy was not helpful in predicting the
response to therapy, although our patients may not be
comparable to his given their limited tubular interstitial
disease. In our study, the mean time from biopsy to start of
treatment was 13 months, with only four patients having had
a biopsy more than 12 months before the date of beginning
of treatment. Of these four patients, two responded and two
did not, although length of time from biopsy to study entry
does not necessarily correlates with development of more
fibrosis. Overall, there was no statistical difference in the
degree of interstitial fibrosis between the responders (inters-
titial fibrosis (IF)¼ 5.5%) versus the non-responders
(IF¼ 6.7%) group, and in contrast to Ruggenenti et al.,
two of our patients with interstitial fibrosis p5% had no
response to treatment. Our results are consistent with our
recent data that suggest that chronic changes observed at
presentation relate more closely to pre-existing patients
factors such as age and hypertension rather than the effects of
the IMN disease itself. These changes did not preclude a
remission of proteinuria among those who received im-
munosuppressive therapy.27 Similar to previous reports, we
also found CD20þ B-cell infiltrates present in renal biopsies
of some patients with IMN.12 However, we found no
correlation between the degree of the CD20þ cell infiltrates,
or CD3þ cell infiltrates, and the response to therapy. It is
possible that with larger numbers of patients some of these
factors would be significant, since there was a tendency to a
better response in those patients with both lower baseline
proteinuria (CR or PR in 6/7 patients with o10 g per 24 h
versus only 3/8 with 410 g per 24 h) (Table 2) and with a
higher creatinine clearances at baseline (97.4725 versus
68.6724 ml per min per 1.73 m2, respectively; P¼ 0.077).
The results of our study appear to support a role for
rituximab in IMN, and does offers a more selective treatment
approach.2 Rituximab was well tolerated with infusion
reactions being the most common side effects. In contrast to
the current, nonspecific, immunosuppressive options and their
associated side effects (renal toxicity, leucopenia, cancer,
infections), rituximab has been given to over half a million
patients with hematological malignancies as well as to a
number of patients with a variety of autoimmune diseases, and
it has been found to be a well-tolerated drug.28 Major
contraindications to its use include the presence of malignancy,
active infection including hepatitis B, and human immuno-
deficiency virus infection, and pregnancy. However, these results
do introduce the need for caution prior to widespread use and
the need for proper randomized trials given our current
inability to predict responders. It is of interest to note that the
approximately 40% with no response is not dissimilar to other
agents and may reflect differing etiologies to IMN disease or
unique factors related to progression not yet identified.
In conclusion, rituximab appears to be effective in
achieving a CR or PR of proteinuria in approximately 60%
of these severely affected membranous patients. The bene-
ficial effect likely results from the depletion of B-cell clones
responsible for producing pathogenic auto-antibodies. We
found that proteinuria appears to have a significant effect on
the PK and PD of rituximab, and this may be important in
terms of its therapeutic effects. However, despite our
extensive measurements of these parameters, we found no
relationship between response and initial proteinuria, time to
B-cell recovery, the development of antibodies to rituximab,
B-cell count in the kidney tissue, nor the degree of tubular
interstitial damage present. A clear conclusion for efficacy,
however, cannot be obtained from an uncontrolled study,
and definitive claims of efficacy should be reserved for
rigorous, prospective, controlled, and randomized trials with
the use of rituximab and that will also look for factors that
may determine its efficacy in IMN.
METHODS
Patient population
Patients included in the study met the following criteria: (1) biopsy-
proven IMN; (2) creatinine clearance X30 ml per min per 1.73 m2;
and (3) persistent proteinuria 45 g per 24 h despite treatment with
an HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase
inhibitor, an ACEi, and/or ARB at maximal tolerated dose for at
least 4 months. The Mayo Institutional Review Board and the
Research Ethical Board, University Health Network, University of
Toronto approved the study protocol. All patients gave written
informed consent. Patients who had been on treatment with
prednisone, cyclosporine, or mycophenolic mofetil within the last 4
months or alkylating agents within the last 6 months were not
included in the study. Patients with active infection, diabetes,
or a secondary cause of MN (for example, hepatitis B, systemic
lupus erythematosus (SLE), medications, malignancies) were also
excluded.
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Treatment
At enrollment, a low-sodium (o4 g day1) and low-protein (0.8 g per
kg per day of high-quality protein) diet was recommended and patients
were encouraged to maintain the same diet throughout the duration of
the study. All patients received a similar conservative treatment regimen
that included loop diuretics to control edema, an HMG-CoA reductase
inhibitor, and an ACEi combined with an ARB if tolerated. b-Blockers
and non-dihydropyridine calcium channel blockers, in that order, were
added when required to control systolic blood pressures to o135 mm
Hg in 475% of the readings. Patients who after a minimum of 4
months of conservative therapy and maximized Ang II blockade had
proteinuria 45 g per 24 h received two i.v. infusions of rituximab at a
dose of 1000 mg on days 1 and 15. To minimize infusion reactions,
patients were premedicated with acetaminophen (1000 mg) and
diphenhydramine hydrochloride (50 mg) orally. In addition, methyl-
prednisolone (100 mg, i.v.) was given prior to the first rituximab
infusion. B-cell depletion was defined as CD19þ counto5 cells per ml
at any time and B-cell recovery was defined as CD19þ cell count
415 cells per ml. Patients treated with rituximab, who at month 6 had
proteinuria 43 g per 24 h and in whom CD19þ B-cell counts had
increased to 415 cells per ml, received a second course of rituximab
treatment following the same protocol described above.
Follow-up
In all patients, clinical and laboratory parameters including
complete blood counts, electrolytes, serum albumin, B-cell flow
cytometry for CD19þ B cells, serum immunoglobulin (IgG, IgM,
IgA) levels, and a lipid panel were evaluated at study entry and at
months 1, 3, 6, 9, and 12. Creatinine clearance and protein and
creatinine excretion in the urine were assessed by performing two
consecutive 24-h urine collections at each time point. Data were
considered accurate when urinary creatinine excretion was con-
sistent with a complete 24 h collection. The mean of the two
measurements was considered for the analysis. The presence of
HACAs was evaluated at baseline and at months 3, 6, 9, and 12.
Rituximab pharmacokinetic assay. Serum rituximab levels
were quantified by a proprietary enzyme-linked immunosorbent
assay at Genentech Inc. (South San Francisco, CA, USA). The assay
uses a proprietary polyclonal goat anti-rituximab antibodies
developed at Genentech Inc. as the capture reagent and goat
antibody to mouse IgG F(ab)2 (Jackson ImmunoResearch Labora-
tories Inc., West Grove, PA, USA) conjugated to horseradish
peroxidase (Jackson ImmunoResearch Laboratories Inc.) as the
detection reagent. The assay has a sensitivity of 500 ng ml1.
Human anti-chimeric antibody assay. The HACA assay is a
proprietary bridging enzyme-linked immunosorbent assay per-
formed at Genentech Inc. that measures the antibody response to
rituximab in human serum samples. The assay uses rituximab as the
capture reagent and biotinylated rituximab and streptavidin–horse-
radish peroxidase (Jackson ImmunoResearch Laboratories Inc.) for
detection. A calibrator curve is prepared with proprietary goat
polyclonal antibodies to rituximab; therefore, the results from this
assay are reported relative to this polyclonal antibody in relative
units per milliliter (RU ml1). The calibrator curve sensitivity is
5.0 RU ml1 (approximately 5 ng ml1 of goat polyclonal antibodies
to rituximab). All positive antibody responses are confirmed by
immunodepletion with rituximab.
Immunohistochemistry and assessment of interstitial fibrosis
All kidney biopsies were routinely processed for light, immuno-
fluorescence, and electron microscopy. In addition, tissues were
stained for infiltrating lymphocytes (CD20 and CD3), and the
amount of interstitial fibrosis was quantified by histomorphometry.
Formalin-fixed, paraffin-embedded sections were cut onto coated
glass slides. Following heat-induced antigen retrieval, sections were
incubated at 201C overnight with either anti-CD20 primary antibody
or anti-CD3 primary antibody, both at 1:1000 dilution (Dako,
Canada Inc, Mississauga, Ontario, Canada). After rinsing all sections,
pretreatment with 3% hydrogen peroxide was performed to prevent
endogenous peroxidase activation. Sections were incubated with a
secondary rabbit anti-mouse antibody linked with avidin–biotin
complex. Sections were counterstained with hematoxylin and
examined by light microscopy. CD20þ cells (B cells) and CD3þ
cells (T cells) were manually counted and the density of positive cells
per area of renal cortex was calculated utilizing Image Pro Plus
(Media Cybernetics: Media Cybernetics Inc, Bethesda, MD, USA)
computer image analysis software. Assessment of degree of interstitial
fibrosis was performed on formalin-fixed, paraffin-embedded section
stained with Picric-Sirius Red. The entirety of sampled and stained
renal cortex for each case was photographed and analyzed using
Image Pro Plus (Media Cybernetics), carefully excluding renal
medullary tissue, as previously described.29 This computer software
was used to analyze the percentage of red-staining renal cortex
compared to the total cortical area in the biopsy and was expressed as
a fractional portion of red-staining cortex compared to cortical biopsy
area Andrew Herzenberg (AH).
Statistical considerations
The primary efficacy parameter was defined as change in urinary
protein excretion from baseline (week 0) to 12 months after
treatment. The 12-month changes were tested against zero using the
paired t-test. Secondary end points included 6-month changes in
protein; the number with PR or CR at 6 or 12 months; and changes
in glomerular filtration rate (GFR), serum albumin, and lipid
profiles. Study sample size was based on the desire to have 80%
power to detect a drop in urinary protein of at least 2.0 g day1.
Assuming a two-sided hypothesis test performed at a significance
level of 0.05 and an s.d. of urinary protein change of 2.5 g, it was
determined that 15 patients were required.2 Definition of remission
status is according to the criteria established by Cattran et al.30 CR
was defined as proteinuria o0.3 g per 24 h, PR as proteinuria p3 g
per 24 h, and a 450% reduction in peak proteinuria and non-
response as o50% reduction in peak proteinuria. Any patient
reaching a CR or PR was considered a treatment success.
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